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ABSTRACT
Background
Current animal models of human cardiac disease may be similar in anatomy and
physiology but are often expensive and tedious to work with. The current need is for a model
organism that is more efficient to work with in the lab while still providing an accurate model of
human cardiac disease. Drosophila melanogaster (D. mel) is such a candidate. While 74% of the
genes coding for protein are conserved between D. mel and human hearts, it is unknown if
cardiac medication used in humans, such as atropine and propranolol hydrochloride, similarly
affect heart rate. I hypothesized that administration of atropine and propranolol hydrochloride
to third instar larvae would cause an increase and decrease respectively in the heart rates of D.
mel.
Methods
After larvae hatched and reached the second instar larval phase, they were moved to
fresh vials. The control group larvae were transferred to vials containing no medication and the
experimental group larvae were transferred to vials with 1mM atropine or 1mM propranolol
hydrochloride. The larvae inhabited the new vials for 24 hours to reach the third instar larvae
stage. Larvae were removed, placed individually on a microscope slide, and observed using the
4X objective lens of a Leica compound microscope. Heart rates of 50 larvae per group were
recorded in triplicate over 15 second intervals.
Results
We observed elevated heart rates of 406 ± 3.18 beats per minute in atropine treated
larvae when compared to rates of 388 ± 2.07 in control larvae, a 4.83% increase. Moreover,
heart rates were slowed to an average of 274 ± 2.70 beats per minute in propranolol
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hydrochloride treated hearts, a 29.18% decrease. Both changes in heart rate when compared to
the control were found to be statistically significant (p<0.001).
Conclusion
Administration of propranolol hydrochloride and atropine increased and decreased the
heart rates of D. mel respectively. This data supports the hypothesis that D. mel can serve as an
experimental model for human cardiovascular disease. Future work should build on this study
and focus on the use of D. mel in preliminary pharmaceutical testing for new medication
treating cardiovascular conditions.

Keywords: drosophila menanogaster, atropine, propranolol hydrochloride, heart rate
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INTRODUCTION
Models of Cardiovascular Disease
According to the American Heart Association, one American dies of cardiac disease
every 40 seconds (Mozaffarian et al., 2015), and the causation, prevention, and treatment of
cardiac disease are areas of active research. Organisms of mammalian origin are predominantly
chosen for studying cardiac disease and include baboons, pigs, sheep, dogs, rabbits, rats, and
mice (Hasenfuss, 1998). Mammals are typically used due to their similarity in physiology, making
them candidates to research new treatment methods (Patel et al., 2001). Smaller mammals,
such as rats and mice, are also useful because they can be genetically manipulated, and
subsequently used to determine the effects of mutations in genes relating to cardiac function
(Rosenthal & Brown, 2007). Similarly, zebrafish have recently emerged as another model for
human cardiac disease research and have been used to model congenital heart defects and
cardiomyopathies, as well as to determine mechanisms that can lead to cardiac disease
(Bakkers, 2011).
These organisms have been pivotal in developing current knowledge regarding the
physiology of the human cardiovascular system as well as the development and treatment of
cardiovascular disease. Unfortunately, many of these organisms are inefficient to use in the
laboratory. Costs to obtain and maintain these organisms in a laboratory setting are not trivial.
According to the Jackson Laboratory website, purchasing mice for research would cost
approximately $10.75 per mouse (“Jax mice pricing information”, 2018). Genetically modified
mice are even more expensive, and according to the Cyagen Biosciences website, could range
from $250 to nearly $7,000 depending on the desired method of inserting genes into the mouse
genome (“Regular transgenic mice”, 2018). Rabbits, according to the Charles River website,
range from $160 to $330 per rabbit depending on the weight (“New Zealand white rabbit”,
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2018) . In addition, many of these animals can be difficult to handle and manage within the lab
to ensure they are cared for humanely throughout research. Mice, for example, can move
quickly and may attempt to bite the hands of researchers while handling (Buerge and Weiss,
2004). Dogs and primates, according to the Johns Hopkins University Animal Care and Use
Committee, may require tranquilization if they are aggressive and difficult to work with. To
advance research in this area, it would be advantageous to find an organism that is more
efficient to utilize in the lab while still providing an accurate model of human cardiac disease.
Drosophila melanogaster
D. mel is a candidate for modeling human cardiac disease and is an efficient organism to
use in the lab for many reasons. One reason it is efficient is the well documented short lifespan
of the organism (Linford et al., 2013). D. mel is used as a model of aging due to its short life span
of approximately 50 days from fertilization of the egg to the death of the adult fly. This lifespan
is significantly lower than those of typical mammals. A rat, for example, has an estimated mean
life expectancy of 22 months (Baati et al., 2012). A shorter lifespan allows researchers to study
organisms in different stages of life over a shorter amount of time.
Another contributor to the efficiency of using D. mel is the immense research that has
been done to sequence the genome of the organism (Pandey & Nichols, 2011). Scientists know
many of the genes in the DNA of D. mel and are then able to use this information to determine
whether genes code for disease or for resistance to disease. Further, D. mel can incur mutations
in genes homologous to genes of human disease naturally or by manipulation (Bier & Bodmer,
2004). This ability allows D. mel to be a model for discovering the outcome of mutations in
genes necessary for physiological function and maintenance of health.
Further benefits include the feasibility of raising the organisms in lab and the
inexpensive cost (Doke & Dhawale, 2015). D. mel, in contrast to the prices of mammalian
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models, can be purchased for $8.10 per vial containing 25 to 30 flies for moth wildtype and
mutant strains. In addition, all of the materials necessary for culturing can be purchased for
$65.50 (“Carolina easy fly drosophila cultures, living”, 2018).
In addition to being a practical organism to work with, D. mel is a candidate for human
cardiac disease research. A study performed by Cammarato et al. (2011) determined that the
proteome, or complete protein makeup, of the D. mel heart contains 498 genes vital to heart
function. 74 of these genes (15%) were protein products that are also produced in humans.
Additionally, 73% of the genes were determined to be orthologs of genes found in humans and
mice. Other experiments researching the genetic makeup of the D. mel heart have shown that
they are physiologically similar to human hearts. The hearts of D. mel can develop structural
defects and suffer from arrhythmias (irregular heartbeats) or cardiomyopathies (hereditary
cardiac disease) (Pandey & Nichols, 2011). Another study used D. mel to model the development
of age-related heart failure (Ocorr, Akasaka, & Bodmer, 2007). Due to genetic similarity, D. mel
hearts develop heart failure caused by errors in pacing as well as arrhythmias, key factors in
researching age-related heart failure. This research suggests that D. mel has a promising future
in determining genetic contributions to cardiac disease. Anatomically, however, the heart of D.
mel is different from that of a human (Figure 1).

Figure 1 D. mel cardiac tube captured during the recording of
heart rate. The image was taken of a D. mel larvae under the 4X
objective lens of a Leica compound microscope. The outline of
the head of the cardiac tube can be observed. Surrounding the
cardiac tube is a single layer of cardiomyocytes.
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In a study identifying the genetic components of heart development and function, it was
noted that the D. mel heart has only one chamber, referred to as the cardiac tube, and lacks
coronary arteries (Seyres, Röder, & Perrin, 2012). This structure is different than that of a
human heart, in which there are four highly vascularized chambers. Another study notes that
the D. mel heart has only one layer of cardiomyocytes (heart cells) whereas the human heart
has two sections of cardiomyocytes, the myocardium and endocardium (Medioni et al., 2009).
Despite the anatomical differences, though, the similarity in genetics and proteome present a
convincing case for D. mel as a model of human cardiovascular disease.
Despite current advances in understanding genomic similarities between D. mel and
other organisms typically used as models, it is still not known whether the D. mel cardiovascular
system is capable of responding similarly to heart medication. Understanding physiological
responses of the D. mel heart to heart medication could further qualify it as a model of human
cardiovascular disease and open new doors of research.
Atropine
Atropine is frequently prescribed to increase heart rate in instances of hypotension
(“Atropine,” 2014). The drug is administered to those suffering from bradycardia, a condition of
extremely low heart rate to increase firing of the SA node in the heart (Al, 2014).
Atropine increases heart rate in humans by preventing acetylcholine from binding to
sinoatrial and atrioventricular nodes. It does this by blocking muscarinic acetylcholine receptors
(mAchRs) and, as a result, contraction of these pacemaking nodes increases (Kinkade, 2012). For
this drug to effect D. mel in a similar fashion, the organism must have conserved receptors with
the same capability of being blocked by atropine. One study determined which G-protein
receptors in D. mel were coupled to mAchRs, the active site of atropine (Ren, Folke, Hauser, Li,
& Grimmelikhuijzen, 2015). They found that mammals have five mAchRs and that D. mel has
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only two, an A-type and B-type. Specifically, the A-type mAchRs in D. mel were determined to
have a similar structure to the mammalian receptors. For these receptors to function similarly to
human mAchRs, the D. mel heart would need to be similarly innervated. It was originally
thought that the D. mel heart was not innervated. It was discovered, however, that the D. mel
heart is indeed innervated (Dulcis & Levine, 2003). At the larval stage, heart rate is controlled by
a pacemaker structure thought to be located in the caudal region of the heart. With all of this in
mind, it is still not known whether these receptors can invoke the same response on the
innervating structure of the D. mel heart. If the mAchRs of D. mel can respond to atropine
similarly to humans, this would support our knowledge of D. mel as a model for human cardiac
disease and medicinal research.
Propranolol hydrochloride
While the effect of atropine increases heart rate, propranolol hydrochloride is a βblocker that decreases heart rate and is prescribed by physicians for patients suffering from
heart failure (Coppola, Froio, & Chiumello, 2015). Results of one study suggest that β-blockers
benefit patients by reducing heart rate and thereby inducing relaxation which may have an
effect on diastolic filling of the heart (Dobre et al., 2007).
β-blockers reduce heart rate by blocking beta1-adrenergic receptors (βARs), reducing
sinoatrial node automaticity and therefore heart rate (Gibson & Raphael, 2014). A study
measuring the effects of βARs agonists versus antagonists on D. mel showed that antagonist βblockers, such as propranolol hydrochloride, decreased mortality by 6.4% (Spindler et al., 2013).
The same study also showed that D. mel does not have βARs but possesses a family of G-protein
receptors that are structurally and functionally related to βARs. However, it is not known
whether treatment with propranolol produces an effect on heart rate. If the βAR-like receptors
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in D. mel can respond to propranolol hydrochloride in a similar way to humans, this would
further support D. mel as a model for human cardiac disease and medicinal research.
The Effects of Heart Medication on D. mel
While there is proteomic support for a conserved mechanism of regulation, it is
unknown if heart medications such as atropine and propranolol hydrochloride have a similar
effect on heart rate. We hypothesized that atropine and propranolol hydrochloride in the
growth media of third instar larvae would cause an increase and decrease respectively in the
heart rates of D. mel. Characterization of the pharmacologic activity of these two drugs on D.
mel cardiac activity would further clarify if there are conserved mechanisms of heart rate
regulation between the invertebrate D. mel and mammals and would lend further support to
using D. mel as a model for human cardiac disease.
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METHODS
Materials and D. mel Culturing
Wild type D. mel were purchased from Carolina Biological and atropine and propranolol
hydrochloride were purchased from Sigma Aldrich. To maintain a constant living environment,
the flies were kept at 22°C and transferred to new vials to mate. The vials were made by mixing
equal amounts of Instant Drosophila Medium purchased from Carolina Biological with sterile
deionized water in drosophila culturing vials with sponge plugs. The flies were given several days
to lay eggs, and once larvae were seen in the vials, the adults were moved to new vials to repeat
the process and obtain stock vials of adult flies.
Treatment with Atropine and Propranolol Hydrochloride
The experimental procedure required a time span of seven days to complete (Figure 2)
and was completed three times in succession. On the first day, adult flies from stock vials were
placed in three new vials to mate. Over the following four to five days, the adult flies laid eggs in
the medium that hatched into larvae and began to mature. By the sixth day, the larvae reached
the second instar larval phase. Larvae at this stage were preferred due to their burrowing nature
in which they tunnel deep into their growth media, thereby increasing exposure to medication
in the media. Second instar larvae were transferred to fresh vials that contained the
experimental treatment. For the control group, 50 second instar larvae were moved to vials
containing media made with sterile deionized water. For the first experimental group, 50 second
instar larvae were transferred to vials with 1mM propranolol hydrochloride in the media. For
the second experimental group, 50 second instar larvae were transferred to vials with 1mM
atropine in the media. 1mM concentrations of each medication were utilized after performing a
preliminary test of a tenfold range of molar concentrations, of which 1mM concentrations were
found to display an effect on heart rate without mortality of the larvae. The second instar larvae
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inhabited the new vials for twenty-four hours, maturing into third instar larvae during this time
at which point heart rates were observed.

Figure 2 Timeline of Procedure Detailing When Flies Were Moved to New Vials and When
Heart Rates Were Recorded. On Day 1, adult flies were moved to new vials to mate. Over the
next few days, the flies were left to lay eggs. Once the larvae hatched from the eggs and entered
the second instar larval stage of development, they were moved to fresh media. At this stage,
atropine or propranolol hydrochloride were administered to the media. After 24 hours, the third
instar larval heart rates were recorded.
Heart Rate Assessment of Third Instar Larvae
The heart rate of each third instar larvae of the control and treatment groups was
observed three times in 15 second intervals. Larvae were removed, placed individually on a
microscope slide, and observed using the 4X objective lens of a Leica compound microscope.
Beating hearts were visualized through the transparent skin of the dorsal side when larvae were
placed on their ventral side. Once the microscope was properly focused on the larva, a 15
second timer with a 10 second interval of rest was started. A tap counter was used to count the
number of times the heart beat during each 15 second interval. After a 10 second rest, the
process was repeated until a total of three heart rates had been recorded for the larva.
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Values were averaged for each larva, with the resulting 50 averages used to calculate
the average heart rate and standard error for the group. To determine the significance of the
two experimental groups from the control group, a T-Test was performed. The statistical
analysis was done using Microsoft Excel.
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RESULTS
Second instar D. mel larvae were treated with 1mM atropine or 1mM propranolol
hydrochloride for 24 hours, after which the heart rates of 50 larvae were assessed at the third
instar larval stage for each treatment. These averages were compared to that of untreated
control larvae (Figure 3). Atropine treatment resulted in a heart rate of 406 ± 3.18 beats per
minute, which represented a 4.83% increase in heart rate over control hearts (388 ± 2.07 bpm).
On the contrary, propranolol hydrochloride treated larvae had hearts rates of 275 ± 2.70 beats
per minute, which was a 29.18% decrease in heart rate when compared to controls. Both
changes in heart rate were statistically significant (p<0.001). These results indicate that both
heart rate medications influenced a change in the heart rates of D. mel larvae.

Average Heart Rate of Control, Atropine, and Propranolol
Hydrochloride Groups
Average heart rate (beats/minute) [Standard Error]

450
400
350
300
250
200
150
100
50
0
Contol

Atropine

Propranolol hydrochloride

Figure 3 Atropine and Propranolol Hydrochloride act as respective positive and negative
chrontropes of D. mel heart rates. Average heart rates of treated third instar larvae in the
control, atropine (1mM), and propranolol hydrochloride (1mM) groups were assessed by
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observing the heart rate using the 4X objective lens of a Leica compound microscope. Heart
rates were recorded in triplicate for 50 in each group. Data are presented as mean plus and
minus the standard error. Respective increase and decreases of heart rate due to atropine and
propranolol hydrochloride treatments were statistically significant (p<0.001).
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DISCUSSION
This research aimed to test whether D. mel larvae can respond similarly to humans
when treated with heart medication. We observed a significant difference in the heart rates of
the larvae that were treated with propranolol hydrochloride. Control larvae had an average
heart rate of 388 ± 2.07 beats per minute while the propranolol hydrochloride treated larvae
had an average heart rate of 275 ± 2.70 beats per minute (p<0.001). This supports the
hypothesis that propranolol hydrochloride decreases the heart rate of third instar larvae and
demonstrates that D. mel responds to heart medication similarly as humans. Further, we also
observed a difference in the heart rates of the larvae treated with atropine. Larvae treated with
atropine had an increased heart rate of 406 ± 3.18 beats per minute (p<0.001). This supports the
hypothesis that atropine increases the heart rate of third instar larvae and demonstrates that D.
mel can respond to heart medication similarly as humans.
The effects of the two medications on the heart rates of D. mel support previous work
that demonstrated the conserved mAchRs and βARs in D. mel. One study determined the
protein content of the two mAchRs found in the D. mel genome (Ren et al., 2015). They
concluded that one of the two mAchRs is pharmacologically similar to that of humans, however,
they did not demonstrate that D. mel was capable of responding to atropine in a similar way to
humans. The increase in heart rate due to atropine supports this research, further supporting
the notion that the mAchRs in D. mel are pharmacologically similar to human mAchRs. Another
study used propranolol hydrochloride to study the effects of β-blockers on the lifespan of D. mel
(Spindler et al., 2013). In this research, it is explained that D. mel do not have the same βARs as
humans, but rather utilize a family of G-protein receptors that may function very similarly to
that of humans. The decrease in heart rate due to propranolol hydrochloride that was observed
in this study would support this research and suggest that the heart of D. mel has conserved

13
receptors capable of responding to the β-blocker propranolol hydrochloride in a similar manner
to humans.
To evaluate the similarity between the effects of atropine and propranolol on the heart
rates of D. mel larvae and humans, it is necessary to compare the results of this experiment to
those found by other studies. After the administration of atropine, there was an observed 4.83%
increase in larval heart rate. One study, which measured heart rate after the endobronchial
administration of atropine in humans, found a 16% increase in heart rate at a dosage of 0.02
mg/kg (Paret et al., 1999). The difference between this 16% increase in heart rate from the
observed 4.83% increase in heart rate is due to differences in atropine dose as well as the
method of delivering the medication. Another study found that atropine increased heart rate in
humans by 13.1 beats per minute (bpm) after 80 minutes at a dosage of 0.15 µg/kg/min (Bruck,
Ulrich, Gerlach, Radke, & Brodde, 2003). The difference between the 13.1 bpm increase from
the approximately 18 bmp increase observed in this experiment is due to differences in dose.
There was also an observed 29.18% increase in larval heart rate after the administration of
propranolol hydrochloride. In one study, participants who received 40mg of propranolol
hydrochloride were found to have resting heart rates of 62 bpm after five hours as opposed to
72 bpm in participants who received the placebo (Joannides et al., 2006). The difference in
recorded decrease in heart rate is due to the difference in dose administered and time between
doses. Larvae in this experiment were exposed to propranolol hydrochloride for 24 hours before
heart rate was recorded, however, participants in the study described above were exposed to
the drug for only five hours. This difference in time could influence the observed decrease in
heart rate in the two experiments. Through comparing the results of this experiment to those of
other studies, it is apparent that the effects of the drugs on the heart rates of D. mel larvae are

14
similar. To confirm this conclusion, future studies need to employ concentrations of the drugs
that more closely parallel those used in human studies.
There were limitations in the study design that should be recognized and improved
upon in future research. Most importantly, the research should have been completed as a
blinded study. This would allow for experimental recording of heart rates while unaware of the
group being observed. Performing the experiment in this way would eliminate the possibility of
bias. Further, there are more precise methods of recording heart rate that could have been
used. At heart rates as rapid as that of D. mel, human error in manually counting is inevitable.
With additional funding, software could be purchased which would allow for computergenerated analysis of videos of the beating larval heart that would more accurately assess the
heart rate (Vogler & Ocorr, 2009).
While further research will add to our knowledge in this area, the data collected in this
experiment suggest that the D. mel heart responds to atropine and propranolol hydrochloride as
the human heart does. If this is indeed the case, future research could be performed to discover
whether D. mel has the capability of responding to other heart medications. In the future, D. mel
could be used as a model organism for research being performed on the effects of these heart
medications.
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